Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H16O3 |
| Molecular Weight | 172.2215 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1(CC(O)=O)CCCCC1
InChI
InChIKey=WMJPAYUKEVEBCN-UHFFFAOYSA-N
InChI=1S/C9H16O3/c10-7-9(6-8(11)12)4-2-1-3-5-9/h10H,1-7H2,(H,11,12)
Hexacyclonic Acid (aka gevilon) has been clinically demonstrated to produce hypolipidemic effects. It has been investigated as a treatment for coronary heart disease, and hypertensive disease with severe lipid metabolic disturbances. Gevilon has been found to have a hypolipidemic effect in reducing the levels of total cholesterol, beta-cholesterol, triglycerides, increasing alpha-cholesterol levels and normalizing the atherogenicity coefficient; especially in patients with Type IIb dyslipoproteinemia.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Hypolipidemic effect of gevilon]. | 1993 |
|
| Therapeutic effect of gevilon in patients with hyperlipoproteinaemia. | 1992-04-01 |
|
| [ELECTROENCEPHALOGRAPHIC EXPERIMENTATION WITH 2 NEW ACTIVATORS: TOCEN AND HEXACYCLONATE (GEVILON)]. | 1963 |
|
| Adjunctive treatment of the chronic alcoholic with hexacyclonate sodium. | 1962-05 |
|
| Pharmaco-motivation of the geriatric patient: a preliminary report on hexacyclonate. | 1962-01 |
|
| Effects of hexacyclonate on regressed patients. | 1961-10 |
|
| [Sodium hexacyclonate as coadjuvant in the treatment and rehabilitation of the chronic alcoholic]. | 1961-06-20 |
|
| [Special clinical a spects of old age and their treatment with sodium-beta,beta-pentamethylene-beta-hydroxybutyrate (Gevilon) in internal medicine]. | 1960-10-28 |
Sample Use Guides
Patients with hyperlipoproteinemia were divided according to hyperlipoproteinemia type IIA, IIB, and IV. After one month of isocaloric diet, the patients were given a single night gevilon dose of 900 mg for a period of 3 months. In all groups increased levels of cholesterol, beta-lipoproteins and triglycerides were significantly reduced after 3 months of gevilon treatment. In all patients, the HDL/LDL ratio increased close to normal values.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C83747
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY | |||
|
2K0FP9UB6A
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY | |||
|
DTXSID30225885
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY | |||
|
167168
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY | |||
|
7491-42-1
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY | |||
|
HEXACYCLONATE
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY | |||
|
23444
Created by
admin on Mon Mar 31 18:38:28 GMT 2025 , Edited by admin on Mon Mar 31 18:38:28 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
